Nature Communications: The success of the prostate cancer treatment predictive model paves the way for individualized medicine

（PCa），。，78800。，，。

，78800。，，。，78800。，，。

pixabay.

pixabay.

New classes of androgen inhibitors, such as enzalutamide and abiraterone, are used in CRPC cases.

Patient-derived xenografts (PDX) are used to study and solve tumor intrinsic characteristics and drug response, because they are more representative than models such as two-dimensional cell culture.

The research team led by Dr.

Researchers led by Dr.

Researchers led by Dr.

They first created a new xenograft derived from early-stage patients, and then tested 74 different drugs on the organoids of this graft and other experimental tumor models-a total of 13 were identified to reduce prostate cancer Cell viability compounds.

Establish a new androgen-dependent, patient-derived xenotransplantation method and process for early prostate cancer metastasis

Establish a new androgen-dependent, patient-derived xenotransplantation method and procedure for early stage prostate cancer metastasis Establish a new androgen-dependent, patient-derived xenotransplantation method and procedure for early stage prostate cancer metastasis

Represents the drug sensitivity of organic compounds at different stages of PCa and the identification of new compounds for reuse.

Represents the drug sensitivity of organic compounds at different stages of PCa and the identification of new compounds for reuse.

These results significance lies not only in fruit reuse of drugs, more importantly, to promote the development of new medical research.

"In my clinical activities, I often encounter tumors that are ineffective to various treatments, or do not know which treatment to use.

References: References: the Patient-derived xenografts.
Organoids and Model Response in Prostate Cancer Therapy Nature Communications doi.
org/10.
1038/s41467-021-21300-6" target="_blank" rel="nofollow noopener">10.
1038 / s41467-021-21300-6 in this message